Management of diabetes mellitus-associated atherosclerosis via simvastatin-loaded novasomes

Area of Science:

• Cardiovascular Medicine
• Nanotechnology in Drug Delivery
• Endocrinology

Background:

• Atherosclerosis, a condition of arterial narrowing and blockage, poses a significant and growing global health burden.
• Diabetes mellitus (DM) is a known risk factor that exacerbates atherosclerosis, increasing the complexity of cardiovascular disease management.
• Simvastatin (SVS), an HMG-CoA reductase inhibitor, exhibits cardioprotective, antioxidant, and anti-inflammatory properties beneficial for DM-associated atherosclerosis, but suffers from poor bioavailability and solubility.

Purpose of the Study:

• To develop and evaluate novel nasal simvastatin-loaded nanostructured lipid carriers (SLNs) to overcome the limitations of conventional SVS delivery.
• To enhance the efficacy, solubility, and bioavailability of simvastatin for the treatment of diabetes mellitus-associated atherosclerosis.
• To investigate the therapeutic potential of nasal SLNs as a novel drug delivery system for cardiovascular protection.

Main Methods:

• Development and optimization of simvastatin-loaded SLNs for nasal administration.
• In vivo evaluation of the optimized SLN formulation in an albino Wistar rat model of DM-associated atherosclerosis.
• Assessment of pharmacokinetic parameters, including bioavailability and permeation, alongside therapeutic efficacy markers (cardiac enzymes, lipid profiles, oxidative stress markers).
• Histopathological and toxicity studies to validate safety and effectiveness.

Main Results:

• The optimized nasal SLN formulation demonstrated a significant increase in simvastatin bioavailability (8.23-fold), permeation (4.52-fold), and drug release (3.88-fold) compared to conventional delivery.
• Significant improvements were observed in cardiac markers (CK-MB, LDH), lipid profiles (HDL, LDL, cholesterol, triglycerides), and antioxidant status (glutathione, superoxide dismutase, catalase) in rats treated with nasal SLNs.
• Histopathological and toxicity assessments confirmed the effectiveness and safety of the nasal SLN formulation.

Conclusions:

• Nasal delivery of simvastatin-loaded SLNs represents a promising strategy to enhance therapeutic outcomes for diabetes mellitus-associated atherosclerosis.
• The developed SLN formulation significantly improves simvastatin's pharmacokinetic profile and efficacy, offering a potential advancement in cardiovascular disease treatment.
• This nanocarrier-based approach provides a viable alternative for managing complex cardiovascular conditions linked to metabolic disorders.